Evotec Rallies 4% to Close the Week, Yet Insider Sale and Steep 200-Day Gap Keep Caution Alive

Evotec shares ended the trading week with a sudden burst of strength, gaining 4.04% on Friday to reach €5.28 and clawing back some of the ground lost in recent months. The move pushed the stock into the top echelon of the TecDAX for the session, driven by a combination of increased demand, sector enthusiasm, and an adjusted capital base. Yet the advance sits uncomfortably alongside an insider share disposal that took place only days earlier and a broader technical picture that remains far from healed.

The Friday pop lifted the seven-day performance to a 1.93% gain, a sharp contrast to the 2.03% decline that had marked the previous week. On a monthly basis the stock is now up 4.97%, and it trades comfortably above its 50-day moving average of €4.91 — a short-term bright spot. But the longer view tells a less forgiving story. Year-to-date the shares are still down 4.80%, and over twelve months the loss stands at 22.96%. The gap to the 200-day moving average remains a significant 6.59% to the downside.

The insider transaction added a layer of scrutiny. Dr. Cord Dohrmann, a member of the executive board, sold shares on 20 May in connection with employee and shareholder participation programs, with the disclosure following on 22 May. Such sales are often mechanical — tied to option exercises or tax obligations — and the market did not show a clear negative reaction. Still, they inject a note of caution into a stock that is already navigating a fundamental overhaul.

On the same corporate governance front, Evotec updated its total voting rights to 177,907,695 as of 29 May, reflecting the issuance of subscription shares. The company confirmed that no multiple voting rights exist. While this is a formal administrative step rather than a price catalyst, it keeps the capital structure transparent as the turnaround effort unfolds.

Should investors sell immediately? Or is it worth buying Evotec?

That turnaround, codenamed “Horizon”, is the central operational story. Evotec’s most recent quarterly figures showed group revenues of €156.6 million, while adjusted EBITDA swung to a loss of €21.9 million from a €3.1 million profit in the prior-year period — a comparison distorted by the inclusion of a one-off Sandoz licence sale. The transformation programme aims to re-engineer the cost base, growth profile, and value creation, but it is consuming financial runway. Cash reserves stood at €444.8 million at quarter-end, down from €476.4 million at the close of 2025, a modest decline that underscores the need for visible progress from the restructuring.

Technically, the stock remains in a delicate zone. Earlier in the week it had slipped below its 38-day moving average, and the relative strength index of 59.7 signals neither overheating nor oversold conditions. The annualised monthly volatility of 46.58% points to a name that can whip around sharply on any news — positive or negative.

The broader pharma industry provides structural support for Evotec’s service model. Germany’s pharmaceutical sector contributes roughly €55 billion annually to the economy, with about 20% of revenues ploughed back into research and development. New therapeutic approaches, digitalisation of discovery, and more complex regulatory demands all increase the need for specialised partners. Yet the company’s decision to delist its American Depositary Shares from the Nasdaq Global Select Market, aimed at reducing complexity and costs, may temper international investor interest. US-based holders now face less convenient trading options, potentially narrowing the stock’s appeal.

Evotec at a turning point? This analysis reveals what investors need to know now.

For the moment, the short-term momentum is clearly positive. But the real test lies in whether Evotec can narrow the chasm to its 200-day average and begin delivering quarterly results that demonstrate the Horizon programme is gaining traction. The insider sale and the voting rights update are minor footnotes in a larger narrative that is still being written — one where the chart has provided a flicker of hope, but not yet a conviction call.

Ad

Evotec Stock: New Analysis - 29 May

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...

en | DE0005664809 | EVOTEC | boerse | 69443299 |